Illumina (NASDAQ: ILMN) has developed a targeted set of instruments and chips for organizations conducting larger-scale research in genotyping and gene expression profiling.
Affymetrix has brought a patent suit against Illumina which is scheduled for March 5, 2007. Early decisions have been made in favor of Affymetrix. Further trial dates are to come in Fall 2007. Illumina announced the acquisition of Solexa on November 13, 2006. The deal was completed on January 26, 2007. Solexa is now a wholly owned subsidiary of Illumina. Solexa brings its primary development, Solexa Sequencing, into Illumina's cadre of genotyping technologies.